Patents by Inventor Daulet Kadyl Satpayev

Daulet Kadyl Satpayev has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR SELECTIVE EXPANSION OF DELTA-3 GAMMA DELTA T-CELL POPULATIONS AND COMPOSITIONS THEREOF
    Publication number: 20230257462
    Abstract: The present application is directed to agents that bind an epitope specific to a ?3 ?? TCR. Such agents can be, but are not limited to, an antibody or fragment thereof. Also described herein are methods for using the agents, e.g., to expand or selectively expand ?3 ?? T cells. Also described herein are methods of using expanded ?3 ?? T cells for treatment of a subject in need thereof.
    Type: Application
    Filed: November 15, 2018
    Publication date: August 17, 2023
    Inventors: Aya Jakobovits, Daulet Kadyl Satpayev, Orit Foord, Yifeng Frank Jing, Hui Shao, Jason Michael Romero, Mary Michael Brodey, Matthew Ian Hoopes
  • METHODS FOR SELECTIVE EXPANSION OF GAMMA DELTA T-CELL POPULATIONS AND COMPOSITIONS THEREOF
    Publication number: 20220372439
    Abstract: The present invention relates to methods for the selective expansion of ?? T-cell population(s), compositions and admixtures thereof and methods for using the same as a therapeutic. Non-engineered and engineered, enriched ?? T-cell populations of the disclosure are useful in the treatment of various cancers, infectious diseases, and immune disorders.
    Type: Application
    Filed: April 11, 2022
    Publication date: November 24, 2022
    Inventors: Aya Jakobovits, Orit Foord, Andy An-deh Lin, Marianne Theresa Santaguida, Radhika Chetan Desai, Yifeng Frank Jing, Daulet Kadyl Satpayev, Yan Li
  • Antibodies capable of binding HLA-A2/TyrD in an HLA restricted manner and uses thereof
    Patent number: 11485785
    Abstract: Antibodies capable of binding HLA-A2/Tyrosinase (TyrD) in an HLA restricted manner are provided. Specifically, the antibodies are capable of binding HLA-A2/TyrD369-377 in an HLA restricted manner. Further provided are complementary determining region (CDR) sequences of heavy chain and light chain of antibodies, and methods of using the antibodies for the treatment of cancer.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: November 1, 2022
    Inventors: Aya Jakobovits, Orit Foord, Daulet Kadyl Satpayev, Mira Peled Kamar, Galit Denkberg, Yoram Reiter, Ilan Beer, Keren Sinik, Yael Teboul (Elbaz), Yael Shperber (Sery), Reut Erel Segal, Ravit Oren, Dror Shmuel Alishekevitz
  • Methods for selective expansion of ?? T-cell populations and compositions thereof
    Patent number: 11299708
    Abstract: The present invention relates to methods for the selective expansion of ?? T-cell population(s), compositions and admixtures thereof and methods for using the same as a therapeutic. Non-engineered and engineered, enriched ?? T-cell populations of the disclosure are useful in the treatment of various cancers, infectious diseases, and immune disorders.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: April 12, 2022
    Assignee: ADICET BIO, INC.
    Inventors: Aya Jakobovits, Orit Foord, Andy An-deh Lin, Marianne Theresa Santaguida, Radhika Chetan Desai, Yifeng Frank Jing, Daulet Kadyl Satpayev, Yan Li
  • ANTIGEN BINDING CONSTRUCTS TO TARGET MOLECULES
    Publication number: 20220089730
    Abstract: Antigen binding constructs that bind to desired targets are disclosed, for example antibodies, including antibody fragments (such as scFv and minibodies) that bind to a target molecule, and have one or more of the disclosed hinges are described herein. Methods of use are described herein.
    Type: Application
    Filed: November 15, 2021
    Publication date: March 24, 2022
    Inventors: Chio Mui Chan, Jean Marie Gudas, Tove Olafsen, Daulet Kadyl Satpayev, Michael Yuri Torgov
  • Extension sequences for diabodies
    Patent number: 11266745
    Abstract: Provided herein are diabodies that comprise extension sequences and antigen binding constructs that comprise extension sequences.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: March 8, 2022
    Assignee: ImaginAb, Inc.
    Inventors: Jean Marie Gudas, Daulet Kadyl Satpayev, Tove Olafsen, Alessandro Mascioni, Michael Yuri Torgov
  • Antigen binding constructs to target molecules
    Patent number: 11254744
    Abstract: Antigen binding constructs that bind to desired targets are disclosed, for example antibodies, including antibody fragments (such as scFv and minibodies) that bind to a target molecule, and have one or more of the disclosed hinges are described herein. Methods of use are described herein.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: February 22, 2022
    Assignee: IMAGINAB, INC.
    Inventors: Chio Mui Chan, Jean Gudas, Tove Olafsen, Daulet Kadyl Satpayev, Michael Yuri Torgov
  • Antigen binding constructs to target molecules
    Patent number: 11203639
    Abstract: Antigen binding constructs that bind to desired targets are disclosed, for example antibodies, including antibody fragments (such as scFv and minibodies) that bind to a target molecule, and have one or more of the disclosed hinges are described herein. Methods of use are described herein.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: December 21, 2021
    Assignee: IMAGINAB, INC.
    Inventors: Chio Mui Chan, Jean Gudas, Tove Olafsen, Daulet Kadyl Satpayev, Michael Yuri Torgov
  • COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON-ENGINEERED GAMMA DELTA T-CELLS FOR TREATMENT OF HEMATOLOGICAL TUMORS
    Publication number: 20210388100
    Abstract: Aspects of the invention include compositions and methods for treatment of hematological tumors with engineered or non-engineered ??-T cells. In some embodiments, the ??-T cells comprise a chimeric antigen receptor (CAR) construct. The CAR construct can contain an anti-CD20 binding domain or anti-B cell maturation antigen (BCMA) binding domain, a CD8 hinge and transmembrane domain, a costimulatory domain, a CD3 ? signalling domain, a combination thereof, or all thereof. The CAR construct can contain a domain encoding for a secreted common gamma chain cytokine such as a sIL 15 domain.
    Type: Application
    Filed: October 1, 2019
    Publication date: December 16, 2021
    Inventors: Daulet Kadyl Satpayev, Marissa Ann Herrman, Jason Michael Romero, Yifeng Frank Jing, Zili An, Aya Jakobovits
  • COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON-ENGINEERED GAMMA DELTA T-CELLS FOR TREATMENT OF SOLID TUMORS
    Publication number: 20210388109
    Abstract: Aspects of the invention include compositions and methods for treatment of solid tumors with engineered or non-engineered ??-T cells. In some embodiments, the ??-T cells comprise a chimeric antigen receptor (CAR) construct. The CAR construct can contain an anti-TryD binding domain, a CD8? hinge and transmembrane domain, a costimulatory domain, a 003? signalling domain, a combination thereof, or all thereof. The CAR construct can contain an anti-GPC3 binding domain, a CD8? hinge and transmembrane domain, a costimulatmy domain, a CD3? signalling domain, a combination thereof, or all thereof. The CAR construct can contain a domain encoding for a secreted common gamma chain cytokine such as a sIL 15 domain.
    Type: Application
    Filed: October 1, 2019
    Publication date: December 16, 2021
    Inventors: Daulet Kadyl Satpayev, Marissa Ann Herrman, Jason Michael Romero, Yifeng Frank Jing, Zili An, Aya Jakobovits
  • ANTIBODIES CAPABLE OF BINDING HLA-A2/TYRD IN AN HLA RESTRICTED MANNER AND USES THEREOF
    Publication number: 20200207858
    Abstract: Antibodies capable of binding HLA-A2/Tyrosinase (TyrD) in an HLA restricted manner are provided. Specifically, the antibodies are capable of binding HLA-A2/TyrD369-377 in an HLA restricted manner. Further provided are complementary determining region (CDR) sequences of heavy chain and light chain of antibodies, and methods of using the antibodies for the treatment of cancer.
    Type: Application
    Filed: June 14, 2017
    Publication date: July 2, 2020
    Inventors: Aya Jakobovits, Orit FOORD, Daulet Kadyl Satpayev, Mira Peled Kamar, Galit Denkberg, Yoram Reiter, Ilan Beer, Keren Sinik, Yael Teboul (Elbaz), Yael Shperber (Sery), Reut Erel Segal, Ravit Oren, Dror Shmuel Alishekevitz
  • METHODS FOR SELECTIVE EXPANSION OF GAMMA DELTA T-CELL POPULATIONS AND COMPOSITIONS THEREOF
    Publication number: 20190119634
    Abstract: The present invention relates to methods for the selective expansion of ?? T-cell population(s), compositions and ad-mixtures thereof and methods for using the same as a therapeutic. Non-engineered and engineered, enriched ?? T-cell populations of the disclosure are useful in the treatment of various cancers, infectious diseases, and immune disorders.
    Type: Application
    Filed: May 12, 2017
    Publication date: April 25, 2019
    Inventors: Aya Jakobovits, Orit Foord, Andy An-deh Lin, Marianne Theresa Santaguida, Radhika Chetan Desai, Yifeng Frank Jing, Daulet Kadyl Satpayev, Yan Li
  • EXTENSION SEQUENCES FOR DIABODIES
    Publication number: 20180221507
    Abstract: Provided herein are diabodies that comprise extension sequences and antigen binding constructs that comprise extension sequences.
    Type: Application
    Filed: January 10, 2018
    Publication date: August 9, 2018
    Inventors: Jean Marie Gudas, Daulet Kadyl Satpayev, Tove Olafsen, Alessandro Mascioni, Michael Yuri Torgov
  • ANTIGEN BINDING CONSTRUCTS TO TARGET MOLECULES
    Publication number: 20170051044
    Abstract: Antigen binding constructs that bind to desired targets are disclosed, for example antibodies, including antibody fragments (such as scFv and minibodies) that bind to a target molecule, and have one or more of the disclosed hinges are described herein. Methods of use are described herein.
    Type: Application
    Filed: August 4, 2016
    Publication date: February 23, 2017
    Inventors: Chio Mui Chan, Jean Gudas, Tove Olafsen, Daulet Kadyl Satpayev, Michael Yuri Torgov